Drug Description in Trials / DrugBank / KEGG DRUG
Search results
Showing 1 to 6 of 6 drugs
| No. | DrugBank | 薬物名（臨床試験情報から抽出） | KEGG DRUG | KEGG GENES | KEGG PATHWAY | 指定難病告示番号 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Ascorbic acid | 4件: Acidum ascorbicum Acidum ascorbicum; Ascorbic Acid; Iron; Vitamin C | 1件: Ascorbic acid
Ascorbic acid
💬1. Ascorbic acid
| - | - | 8件: 10 10, 97, 192, 206, 210, 211, 212, 298 💬
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 2 | Bosentan | 2件: Bosentan Bosentan; Tracleer | 2件: Bosentan
Bosentan
,Bosentan 💬 | 2件: EDNRA EDNRA,EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in c ... | 10件: 41 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬2. Bosentan
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 3 | Dexmedetomidine | 4件: Dexdor Dexdor; DEXMEDETOMIDINA; DEXMEDETOMIDINE; DEXMEDETOMIDINE HYDROCHLORIDE | 1件: Dexmedetomidine
Dexmedetomidine
💬3. Dexmedetomidine
| 3件: ADRA2A ADRA2A,ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 14件: 2 2, 4, 6, 21, 34, 46, 70, 107, 113, 171, 212, 215, 226, 280 💬3. Dexmedetomidine
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 4 | Liothyronine | 3件: Liothyronine Liothyronine; Liothyronine sodium; Triiodothyronine | 1件: Liothyronine
Liothyronine
💬4. Liothyronine
| 2件: THRA THRA,THRB 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway 💬 | 4件: 13 13, 78, 210, 212 💬
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 5 | Liothyronine I-131 | 1件: Liothyronine I 131 Liothyronine I 131 | - | - | - | 2件: 210 210, 212 💬
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 6 | Sildenafil | 6件: Mysildecard Mysildecard; Revatio; Sildenafil; Sildenafil citrate; SILDENAFILO; Viagra | 1件: Sildenafil
Sildenafil
💬6. Sildenafil
| 1件: PDE5A PDE5A 💬6. Sildenafil
| 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 17件: 6 6, 46, 50, 51, 85, 86, 90, 113, 210, 211, 212, 225, 226, 278, 294, 299, 301 💬6. Sildenafil
|